Today, cancer is one of the leading causes of death worldwide. Lately, cytokine and chemokine imbalances have gained attention amongst different involved pathways in cancer development and attracted much consideration in cancer research. CXCL16, as a member of the CXC subgroup of chemokines, has been attributed to be responsible for immune cell infiltration into the tumour microenvironment. The aberrant expression of CXCL16 has been observed in various cancers. This chemokine has been shown to play a conflicting role in tumour development through inducing pro-inflammatory conditions. The infiltration of various immune and non-immune cells such as lymphocytes, cancer-associated fibroblasts and myeloid-derived suppressor cells by CXCL16 into the tumour microenvironment has complicated the tumour fate. Given this diverse role of CXCL16 in cancer, a better understanding of its function might build-up our knowledge about tumour biology. Hence, this study aimed to review the impact of CXCL16 in cancer and explored its therapeutic application. Consideration of these findings might provide opportunities to achieve novel approaches in cancer treatment and its prognosis.

中文翻译：

---

CXC趋化因子配体16：癌症中的瑞士军刀趋化因子

今天，癌症是全球主要的死亡原因之一。最近，细胞因子和趋化因子失衡在癌症发展的不同参与途径中引起了人们的关注，并在癌症研究中引起了很多关注。CXCL16 作为 CXC 趋化因子亚组的成员，被认为负责免疫细胞浸润到肿瘤微环境中。已在各种癌症中观察到 CXCL16 的异常表达。这种趋化因子已被证明通过诱导促炎状态在肿瘤发展中发挥着相互矛盾的作用。CXCL16 将各种免疫和非免疫细胞（如淋巴细胞、癌症相关成纤维细胞和髓源性抑制细胞）浸润到肿瘤微环境中，使肿瘤命运复杂化。鉴于 CXCL16 在癌症中的不同作用，更好地了解其功能可能会增加我们对肿瘤生物学的了解。因此，本研究旨在回顾 CXCL16 在癌症中的影响并探索其治疗应用。考虑这些发现可能为实现癌症治疗及其预后的新方法提供机会。